ACC.2024 – Empagliflozin after acute myocardial infarction: Results of the EMPACT-MI Trial
Mirvat Alasnag interviews Javed Butler about the EMPACT-MI trial which he presented at ACC.24. Among patients at increased risk for heart failure after acute MI, treatment with empagliflozin did not lead to a significantly lower risk of a first hospitalization for heart failure or death from any cause than placebo.